Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaron Acquires Bridge China To Become Fully-integrated CRO

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio

You may also be interested in...



Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron

AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.

Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron

AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.

Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff

SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area

Related Content

UsernamePublicRestriction

Register

SC073019

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel